Similar Papers

Paper Title
Journal
Date
Author
Clinical Significance of FLT3 Mutations in a Comprehensive NGS Multicenter Study of AML: HM-Screen-Japan 01
Kentaro Fukushima ... Hirohiko Shibayama
Blood | VOL. 138
Kentaro Fukushima, et. al.Kentaro Fukushima ... Hirohiko Shibayama
05 Nov 2021
Study Of Activity Of E6201, a Dual FLT3 and MEK Inhibitor, In Acute Myelogenous Leukemia With FLT3 Or RAS Mutation
Weiguo Zhang ... Michael Andreeff
Blood | VOL. 122
Weiguo Zhang, et. al.Weiguo Zhang ... Michael Andreeff
15 Nov 2013
SM09419, a Novel, Small-Molecule CDC-like Kinase (CLK) Inhibitor, Demonstrates Strong Inhibition of the Wnt Signaling Pathway and Antitumor Effects in FMS-like Tyrosine Kinase 3 (FLT3)-Mutant Acute Myeloid Leukemia Models
Heekyung Chung ... Steven Cha
Blood | VOL. 134
Heekyung Chung, et. al.Heekyung Chung ... Steven Cha
13 Nov 2019
A Phase 1 Study of Milademetan in Combination with Quizartinib in Patients with Newly Diagnosed (ND) or Relapsed/Refractory (R/R) FLT3-ITD Acute Myeloid Leukemia (AML)
Naval G Daver ... Michael Andreeff
Blood | VOL. 134
Naval G Daver, et. al.Naval G Daver ... Michael Andreeff
13 Nov 2019
View more papers

More From: Blood

Paper Title
Journal
Date
Author
Advances in RNA editing in hematopoiesis and associated malignancies.
Shuangshuang Pu ... Hui Cheng
Blood | VOL. -
Shuangshuang Pu, et. al.Shuangshuang Pu ... Hui Cheng
27 Jan 2025
Protection of β2GPI-Deficient Mice from Thrombosis Reflects a Defect in PAR3-facilitated Platelet Activation.
Paresh P Kulkarni ... Keith R Mccrae
Blood | VOL. -
Paresh P Kulkarni, et. al.Paresh P Kulkarni ... Keith R Mccrae
27 Jan 2025
Babesiosis and Sickle Red blood Cells: Loss of Deformability, Heightened Osmotic fragility, and Hypervesiculation.
Divya Beri ... Cheryl A Lobo
Blood | VOL. -
Divya Beri, et. al.Divya Beri ... Cheryl A Lobo
27 Jan 2025
Platelet activation and signaling in thrombus formation.
Frauke Swieringa ... Alice Assinger
Blood | VOL. -
Frauke Swieringa, et. al.Frauke Swieringa ... Alice Assinger
27 Jan 2025
View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.